Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. James E. DavisChairman, CEO & President | -10,00k | 1,94M | Automatic Disposition | 194,14 | 132,42k | -7,02% |
| 2026-03-05 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -3,88k | 799,68k | Automatic Disposition | 206,21 | 43,29k | -8,22% |
| 2026-03-04 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -3,35k | 687,10k | Sale to Issuer | 204,86 | 43,29k | -7,19% |
| 2026-03-04 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -2,33k | 476,50k | Sale to Issuer | 204,86 | 11,86k | -16,39% |
| 2026-03-05 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -5,56k | 1,15M | Automatic Disposition | 206,21 | 71,62k | -7,20% |
| 2026-03-04 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -5,81k | 1,19M | Sale to Issuer | 204,86 | 71,62k | -7,50% |
| 2026-03-04 | Mr. Sam A. SamadExec. VP & CFO | -7,72k | 1,58M | Sale to Issuer | 204,86 | 33,27k | -18,83% |
| 2026-03-05 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -2,86k | 588,73k | Automatic Disposition | 206,21 | 15,20k | -15,81% |
| 2026-03-04 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -2,83k | 579,14k | Sale to Issuer | 204,86 | 15,20k | -15,68% |
| 2026-03-04 | Mr. James E. DavisChairman, CEO & President | -26,41k | 5,41M | Sale to Issuer | 204,86 | 142,42k | -15,64% |
| 2026-03-04 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -750,00 | 153,65k | Sale to Issuer | 204,86 | 35,90k | -2,05% |
| 2026-03-04 | Mr. Karthik KuppusamySVP of Clinical Solutions | -2,63k | 538,37k | Vente | 204,86 | 15,46k | -14,53% |
| 2026-03-03 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -526,00 | 109,27k | Automatic Disposition | 207,73 | 43,29k | -1,20% |
| 2026-03-02 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -288,00 | 59,00k | Sale to Issuer | 204,86 | 43,29k | -0,66% |
| 2026-03-03 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -632,00 | 131,29k | Automatic Disposition | 207,73 | 71,62k | -0,87% |
| 2026-03-02 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -648,00 | 132,75k | Sale to Issuer | 204,86 | 71,62k | -0,90% |
| 2026-03-02 | Mr. Sam A. SamadExec. VP & CFO | -869,00 | 178,02k | Sale to Issuer | 204,86 | 27,04k | -3,11% |
| 2026-03-03 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -410,00 | 85,17k | Automatic Disposition | 207,73 | 15,20k | -2,63% |
| 2026-03-02 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -230,00 | 47,12k | Sale to Issuer | 204,86 | 15,20k | -1,49% |
| 2026-03-02 | Mr. James E. DavisChairman, CEO & President | -10,00k | 2,13M | Automatic Disposition | 212,52 | 117,19k | -7,86% |
| 2026-03-02 | Mr. James E. DavisChairman, CEO & President | -2,97k | 608,02k | Sale to Issuer | 204,86 | 117,19k | -2,47% |
| 2026-03-02 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -188,00 | 38,51k | Sale to Issuer | 204,86 | 8,51k | -2,16% |
| 2026-03-02 | Mr. Karthik KuppusamySVP of Clinical Solutions | -205,00 | 42,00k | Sale to Issuer | 204,86 | 11,89k | -1,70% |
| 2026-03-02 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -88,00 | 18,03k | Sale to Issuer | 204,86 | 35,18k | -0,25% |
| 2026-02-18 | Mr. Sam A. SamadExec. VP & CFO | -1,87k | 388,62k | Sale to Issuer | 206,99 - 210,01 | 27,84k | -6,28% |
| 2026-02-19 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -958,00 | 196,23k | Automatic Disposition | 204,83 | 15,84k | -5,70% |
| 2026-02-18 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -537,00 | 111,89k | Sale to Issuer | 206,99 - 210,01 | 15,84k | -3,28% |
| 2026-02-18 | Mr. James E. DavisChairman, CEO & President | -6,18k | 1,29M | Sale to Issuer | 206,99 - 210,01 | 130,15k | -4,54% |
| 2026-02-19 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -1,11k | 227,57k | Automatic Disposition | 204,83 | 44,11k | -2,46% |
| 2026-02-18 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -648,00 | 135,04k | Sale to Issuer | 206,99 - 210,01 | 44,11k | -1,45% |
| 2026-02-18 | Mr. Karthik KuppusamySVP of Clinical Solutions | -511,00 | 106,53k | Sale to Issuer | 206,99 - 210,01 | 12,06k | -4,06% |
| 2026-02-19 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -1,43k | 293,52k | Automatic Disposition | 204,83 | 72,91k | -1,93% |
| 2026-02-18 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -1,16k | 241,62k | Sale to Issuer | 206,99 - 210,01 | 72,91k | -1,57% |
| 2026-02-18 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -435,00 | 90,66k | Sale to Issuer | 206,99 - 210,01 | 8,68k | -4,77% |
| 2026-02-18 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -182,00 | 37,92k | Sale to Issuer | 206,99 - 210,01 | 35,27k | -0,51% |
| 2026-02-13 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -26,17k | 2,46M | Derivative Exercise and Sale | 112,17 - 209,10 | 72,57k | - |
| 2026-02-10 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -5,66k | 465,39k | Derivative Exercise and Sale | 121,81 - 204,00 | 15,38k | - |
| 2025-11-25 | Ms. Vicky Brown GreggIndependent Director | -1,25k | 239,70k | Vente | 191,76 | 17,04k | -6,84% |
| 2025-11-25 | Mr. James E. DavisChairman, CEO & President | -55,09k | 5,31M | Derivative Exercise and Sale | 95,80 - 192,97 | 120,48k | - |
| 2025-11-18 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -7,95k | 340,84k | Derivative Exercise and Sale | 143,33 - 187,35 | 7,53k | - |
| 2025-11-05 | Mr. James E. DavisChairman, CEO & President | -7,14k | 1,25M | Sale to Issuer | 175,57 | 120,48k | -5,60% |
| 2025-10-22 | Mr. Gary M. PfeifferIndependent Director | -1,48k | 270,32k | Vente | 182,40 | 29,43k | -4,79% |
| 2025-10-23 | Mr. Gary M. PfeifferIndependent Director | -4,41k | 0,00 | Derivative Disposition Under Employee Benefit Plan | - | 0,00 | -100,00% |
| 2025-09-26 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -227,00 | 19,20k | Derivative Exercise and Sale | 103,57 - 188,66 | 43,81k | - |
| 2025-09-23 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -28,46k | 2,38M | Derivative Exercise and Sale | 103,57 - 187,12 | 43,81k | - |
| 2025-08-21 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 365,38k | Automatic Disposition | 185,00 | 15,27k | -11,45% |
| 2025-08-19 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -4,53k | 321,00k | Derivative Exercise and Sale | 112,17 - 183,00 | 17,24k | - |
| 2025-08-15 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 355,50k | Automatic Disposition | 180,00 | 17,24k | -10,28% |
| 2025-08-13 | Mr. Karthik KuppusamySVP of Clinical Solutions | -123,00 | 21,64k | Sale to Issuer | 175,91 | 10,32k | -1,18% |
| 2025-08-06 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -3,56k | 314,60k | Derivative Exercise and Sale | 86,63 - 175,00 | 19,22k | - |
| 2025-08-06 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 345,63k | Automatic Disposition | 175,00 | 19,22k | -9,32% |
| 2025-07-30 | Mr. Karthik KuppusamySVP of Clinical Solutions | -8,27k | 534,47k | Derivative Exercise and Sale | 86,63 - 167,40 | 10,44k | - |
| 2025-07-31 | Mr. Karthik KuppusamySVP of Clinical Solutions | -2,21k | 375,70k | Automatic Disposition | 170,00 | 10,44k | -17,47% |
| 2025-07-16 | Mr. Sam A. SamadExec. VP & CFO | -850,00 | 143,66k | Sale to Issuer | 169,01 | 25,60k | -3,21% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
